CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
Lawrence D Mayer, Paul Tardi, Arthur C LouieJazz Pharmaceuticals, Inc., Palo Alto, CA, USAAbstract: Combination regimens are a standard of care for many cancers. However, components of such regimens are typically first developed individually and subsequently combined using strategies to minimize tox...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-05-01
|
| Series: | International Journal of Nanomedicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/cpx-351-a-nanoscale-liposomal-co-formulation-of-daunorubicin-and-cytar-peer-reviewed-article-IJN |